110 related articles for article (PubMed ID: 9655845)
1. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
Egan CT; Herrick-Davis K; Teitler M
J Pharmacol Exp Ther; 1998 Jul; 286(1):85-90. PubMed ID: 9655845
[TBL] [Abstract][Full Text] [Related]
2. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Herrick-Davis K; Grinde E; Teitler M
J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
[TBL] [Abstract][Full Text] [Related]
3. Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.
Purohit A; Herrick-Davis K; Teitler M
Synapse; 2003 Mar; 47(3):218-24. PubMed ID: 12494404
[TBL] [Abstract][Full Text] [Related]
4. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
5. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.
Roth BL; Choudhary MS; Khan N; Uluer AZ
J Pharmacol Exp Ther; 1997 Feb; 280(2):576-83. PubMed ID: 9023266
[TBL] [Abstract][Full Text] [Related]
6. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
Rauser L; Savage JE; Meltzer HY; Roth BL
J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066
[TBL] [Abstract][Full Text] [Related]
7. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
Pauwels PJ; Gouble A; Wurch T
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
[TBL] [Abstract][Full Text] [Related]
8. Creation of a constitutively activated state of the 5-HT2A receptor by site-directed mutagenesis: revelation of inverse agonist activity of antagonists.
Egan C; Herrick-Davis K; Teitler M
Ann N Y Acad Sci; 1998 Dec; 861():136-9. PubMed ID: 9928250
[TBL] [Abstract][Full Text] [Related]
9. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Egan C; Grinde E; Dupre A; Roth BL; Hake M; Teitler M; Herrick-Davis K
Synapse; 2000 Feb; 35(2):144-50. PubMed ID: 10611640
[TBL] [Abstract][Full Text] [Related]
10. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.
Kristiansen K; Kroeze WK; Willins DL; Gelber EI; Savage JE; Glennon RA; Roth BL
J Pharmacol Exp Ther; 2000 Jun; 293(3):735-46. PubMed ID: 10869371
[TBL] [Abstract][Full Text] [Related]
11. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Cussac D; Duqueyroix D; Newman-Tancredi A; Millan MJ
Psychopharmacology (Berl); 2002 Jul; 162(2):168-77. PubMed ID: 12110994
[TBL] [Abstract][Full Text] [Related]
12. Mutagenesis analysis of the serotonin 5-HT2C receptor and a Caenorhabditis elegans 5-HT2 homologue: conserved residues of helix 4 and helix 7 contribute to agonist-dependent activation of 5-HT2 receptors.
Xie J; Dernovici S; Ribeiro P
J Neurochem; 2005 Jan; 92(2):375-87. PubMed ID: 15663485
[TBL] [Abstract][Full Text] [Related]
13. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
Weiner DM; Burstein ES; Nash N; Croston GE; Currier EA; Vanover KE; Harvey SC; Donohue E; Hansen HC; Andersson CM; Spalding TA; Gibson DF; Krebs-Thomson K; Powell SB; Geyer MA; Hacksell U; Brann MR
J Pharmacol Exp Ther; 2001 Oct; 299(1):268-76. PubMed ID: 11561089
[TBL] [Abstract][Full Text] [Related]
14. Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization.
Gray JA; Compton-Toth BA; Roth BL
Biochemistry; 2003 Sep; 42(36):10853-62. PubMed ID: 12962510
[TBL] [Abstract][Full Text] [Related]
15. Activating mutations of the serotonin 5-HT2C receptor.
Herrick-Davis K; Egan C; Teitler M
J Neurochem; 1997 Sep; 69(3):1138-44. PubMed ID: 9282936
[TBL] [Abstract][Full Text] [Related]
16. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
Westphal RS; Backstrom JR; Sanders-Bush E
Mol Pharmacol; 1995 Aug; 48(2):200-5. PubMed ID: 7651352
[TBL] [Abstract][Full Text] [Related]
17. Differences in rapid desensitization of 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor-mediated phospholipase C activation.
Berg KA; Stout BD; Maayani S; Clarke WP
J Pharmacol Exp Ther; 2001 Nov; 299(2):593-602. PubMed ID: 11602671
[TBL] [Abstract][Full Text] [Related]
18. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
19. Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
Purohit A; Smith C; Herrick-Davis K; Teitler M
Psychopharmacology (Berl); 2005 May; 179(2):461-9. PubMed ID: 15821958
[TBL] [Abstract][Full Text] [Related]
20. Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis.
Ganguli SC; Park CG; Holtmann MH; Hadac EM; Kenakin TP; Miller LJ
J Pharmacol Exp Ther; 1998 Aug; 286(2):593-8. PubMed ID: 9694908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
